Compare Kroger Co (KR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Zoetis Inc — how do they compare? Kroger Co trades at $61.35 (market cap $36.27B), while Zoetis Inc trades at $74.58 (market cap $30.20B). The key difference: Kroger Co is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and Zoetis Inc for 70 Days on average.
| KR | ZTS | |
|---|---|---|
Market Cap | $36.27B | $30.20B |
Volume | 8,301,523 | 6,175,327 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $147.53 |
52-Week Low | $55.53 | $69.09 |
Typical Hold Time | 108 Days | 70 Days |
Enterprise Value | $57.69B | $37.76B |
Dividend Yield | 2.54% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.04, up 3.02% with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with $147.12B revenue, 14.24% ROE, and consistent dividend payments. Recent earnings beat expectations in two of the last three quarters, while the company demonstrates strong cash flow generation with $5.79B from operations in 2025. Technical indicators show the stock trading near pivot point resistance at $62 with bullish moving average alignment.
Kroger presents a compelling value opportunity with low P/S ratio of 0.26 and 47.7% analyst buy ratings, though near-term risks include integration challenges from the Giant Eagle acquisition and cost pressures. The consensus price target of $70.62 suggests 15.7% upside potential, supported by digital growth initiatives and retail media expansion, but investors should monitor identical sales trends and margin pressures in the competitive grocery sector.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
